UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Repositioning metformin for cancer prevention and treatment

Trends in endocrinology and metabolism, 2013-09, Vol.24 (9), p.469-480

2013

Volltextzugriff (PDF)

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

Journal of thoracic oncology, 2021-07, Vol.16 (7), p.1086-1098

2021

Volltextzugriff (PDF)

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

Cellular signalling, 2009-05, Vol.21 (5), p.656-664

2009

Volltextzugriff (PDF)

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

Cancer prevention research (Philadelphia, Pa.), 2010-09, Vol.3 (9), p.1066-1076

2010

Volltextzugriff (PDF)

The Role of the Akt/mTOR Pathway in Tobacco Carcinogen–Induced Lung Tumorigenesis

Clinical cancer research, 2010-01, Vol.16 (1), p.4-10

2010

Volltextzugriff (PDF)

A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

The oncologist (Dayton, Ohio), 2019-12, Vol.24 (12), p.1510-e1265

2019

Volltextzugriff (PDF)

Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

Clinical cancer research, 2006-02, Vol.12 (3), p.679-689

2006

Volltextzugriff (PDF)

A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity

Nucleic acids research, 2008-04, Vol.36 (6), p.1755-1769

2008

Volltextzugriff (PDF)

Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

Journal of the National Comprehensive Cancer Network, 2023-11, Vol.21 (11), p.1164-1171.e5

2023

Volltextzugriff (PDF)

A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis

PloS one, 2009-03, Vol.4 (3), p.e5061

2009

Volltextzugriff (PDF)

LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin

Journal of clinical oncology, 2009-12, Vol.27 (34), p.e226; author reply e227-e226

2009

Volltextzugriff (PDF)

Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling

Cancer prevention research (Philadelphia, Pa.), 2013-08, Vol.6 (8), p.801-810

2013

Volltextzugriff (PDF)

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

Oncotarget, 2014-02, Vol.5 (4), p.1062-1070

2014

Volltextzugriff (PDF)

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer

Translational lung cancer research, 2019-06, Vol.8 (3), p.247-257

2019

Volltextzugriff (PDF)

The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers

Cancer prevention research (Philadelphia, Pa.), 2009-04, Vol.2 (4), p.370-376

2009

Volltextzugriff (PDF)

Phosphatidylinositol Ether Lipid Analogues Induce AMP-Activated Protein Kinase-Dependent Death in LKB1-Mutant Non-Small Cell Lung Cancer Cells

Cancer research (Chicago, Ill.), 2008-01, Vol.68 (2), p.580-588

2008

Volltextzugriff (PDF)

Abstract 1110: Targeting β-catenin enhances the therapeutic efficacy of osimertinib in EGFR- mutant non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1110-1110

2021

Volltextzugriff (PDF)

Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2626-2626

2023

Volltextzugriff (PDF)

PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e16-e16

2024

Volltextzugriff (PDF)

Eosinophil-neutrophil ratio as a sex-dependent prognostic marker in immune checkpoint therapy for metastatic NSCLC and transcriptomic evaluation of intratumoral eosinophil-T cell interaction

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8586-8586

2024

Volltextzugriff (PDF)

A multi-center cohort study Examining risk factors for central nervous system metastases (CNSm) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation (ChemoRT) followed by durvalumab (Durva)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8076-8076

2024

Volltextzugriff (PDF)

CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment

Journal of the National Comprehensive Cancer Network, 2024-04, Vol.22 (2.5)

2024

Volltextzugriff (PDF)

Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20605-e20605

2023

Volltextzugriff (PDF)

Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21094-e21094

2023

Volltextzugriff (PDF)

Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9067-9067

2023

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Repositioning metformin for cancer prevention and treatment

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

The Role of the Akt/mTOR Pathway in Tobacco Carcinogen–Induced Lung Tumorigenesis

A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity

Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis

LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin

Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer

The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers

Phosphatidylinositol Ether Lipid Analogues Induce AMP-Activated Protein Kinase-Dependent Death in LKB1-Mutant Non-Small Cell Lung Cancer Cells

Abstract 1110: Targeting β-catenin enhances the therapeutic efficacy of osimertinib in EGFR- mutant non-small cell lung cancer (NSCLC)

Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC

PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy

Eosinophil-neutrophil ratio as a sex-dependent prognostic marker in immune checkpoint therapy for metastatic NSCLC and transcriptomic evaluation of intratumoral eosinophil-T cell interaction

A multi-center cohort study Examining risk factors for central nervous system metastases (CNSm) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation (ChemoRT) followed by durvalumab (Durva)

CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment

Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva)

Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC)

Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC

Suchergebnisse filtern